These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 27400657)

  • 1. Implementation of immunochemical faecal occult blood test in general practice: a study protocol using a cluster-randomised stepped-wedge design.
    Juul JS; Bro F; Hornung N; Andersen BS; Laurberg S; Olesen F; Vedsted P
    BMC Cancer; 2016 Jul; 16():445. PubMed ID: 27400657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of direct referral for fast CT scan in early lung cancer detection in general practice. A clinical, cluster-randomised trial.
    Guldbrandt LM
    Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal screening using the immunochemical faecal occult blood test kit among the Malaysian cohort participants.
    Abdullah N; Abd Jalal N; Ismail N; Kamaruddin MA; Abd Mutalib NS; Alias MR; Mazlan L; Sagap I; Jamal R
    Cancer Epidemiol; 2020 Apr; 65():101656. PubMed ID: 31923638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revised Australian national guidelines for colorectal cancer screening: family history.
    Jenkins MA; Ait Ouakrim D; Boussioutas A; Hopper JL; Ee HC; Emery JD; Macrae FA; Chetcuti A; Wuellner L; St John DJB
    Med J Aust; 2018 Nov; 209(10):455-460. PubMed ID: 30359558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
    Van Roosbroeck S; Hoeck S; Van Hal G
    Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms.
    Tikk K; Czock D; Haefeli WE; Kopp-Schneider A; Brenner H
    BMC Cancer; 2018 Sep; 18(1):914. PubMed ID: 30249195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could it be colorectal cancer? General practitioners' use of the faecal occult blood test and decision making--a qualitative study.
    Högberg C; Samuelsson E; Lilja M; Fhärm E
    BMC Fam Pract; 2015 Oct; 16():153. PubMed ID: 26498374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of immunochemical faecal occult blood testing for colorectal cancer screening in Bulgaria.
    Tsvetanova Dimova R; Dimitrova Dimitrova D; Angelova Levterova B; Stoyanov Dimov R; Atanasova Semerdjieva M; Frantova Tarnovska M; Gencheva Stoyanova R
    J BUON; 2015; 20(2):413-20. PubMed ID: 26011330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemical faecal occult blood tests in primary care and the risk of delay in the diagnosis of colorectal cancer.
    Högberg C; Karling P; Rutegård J; Lilja M; Ljung T
    Scand J Prim Health Care; 2013 Dec; 31(4):209-14. PubMed ID: 24191847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of population screening for colorectal cancer by repeated fecal occult blood test in the Netherlands.
    Denters MJ; Deutekom M; Fockens P; Bossuyt PM; Dekker E
    BMC Gastroenterol; 2009 Apr; 9():28. PubMed ID: 19393087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal occult blood screening: knowledge, attitudes, and practice in four Hong Kong primary care clinics.
    Tam TK; Ng KK; Lau CM; Lai TC; Lai WY; Tsang LC
    Hong Kong Med J; 2011 Oct; 17(5):350-7. PubMed ID: 21979470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Well adjusted qualitative immunochemical faecal occult blood tests could be a promising alternative for inexpensive, high-quality colorectal cancer screening.
    Tao S; Brenner H
    Eur J Cancer Prev; 2013 Jul; 22(4):305-10. PubMed ID: 23702679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Faecal occult blood test for colorectal cancer screening: high quality for a good price].
    van Veldhuizen H; Bonfrer JM; Kuipers EJ
    Ned Tijdschr Geneeskd; 2013; 157(16):A6330. PubMed ID: 23594877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
    J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in diagnostic activity in general practice and findings for individuals invited to the danish screening programme for colorectal cancer: a population-based cohort study.
    Juul JS; Andersen B; Laurberg S; Carlsen AH; Olesen F; Vedsted P
    Scand J Prim Health Care; 2018 Sep; 36(3):281-290. PubMed ID: 29929415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alerts in electronic medical records to promote a colorectal cancer screening programme: a cluster randomised controlled trial in primary care.
    Guiriguet C; Muñoz-Ortiz L; Burón A; Rivero I; Grau J; Vela-Vallespín C; Vilarrubí M; Torres M; Hernández C; Méndez-Boo L; Toràn P; Caballeria L; Macià F; Castells A
    Br J Gen Pract; 2016 Jul; 66(648):e483-90. PubMed ID: 27266861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of a risk assessment and decision support tool (CRISP) compared with usual care in general practice to increase risk-stratified colorectal cancer screening: study protocol for a randomised controlled trial.
    Walker JG; Macrae F; Winship I; Oberoi J; Saya S; Milton S; Bickerstaffe A; Dowty JG; De Abreu Lourenço R; Clark M; Galloway L; Fishman G; Walter FM; Flander L; Chondros P; Ait Ouakrim D; Pirotta M; Trevena L; Jenkins MA; Emery JD
    Trials; 2018 Jul; 19(1):397. PubMed ID: 30045764
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.